Neoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast Cancer
1/2상
조기 종료
NCT04331067
| 대상 질환 | Triple Negative Breast Cancer |
|---|
| 임상 단계 | 1/2상 |
|---|
| 스폰서 | Washington University School of Medicine |
|---|
| 상태 | 조기 종료 |
|---|
| 참여자 수 | 15 명 |
|---|
| 중재(약물) | Paclitaxel, Carboplatin, Nivolumab, Cabiralizumab, Tumor biopsy |
|---|
| 시작일 | 2020년 11월 19일 |
|---|
| 완료일 | 2023년 3월 20일 |
|---|
| 결과 공개일 | 2024년 5월 16일 |
|---|
요약
Prior to Amendment #7: The hypothesis of this study is that the combination of cabiralizumab and nivolumab with neoadjuvant chemotherapy will decrease tumor associated macrophages (TAMs) and increase tumor infiltrating lymphocytes (TIL) compared to neoadjuvant chemotherapy plus nivolumab in patients with early stage triple-negative breast cancer (TNBC) and improve clinical outcomes. As of Amendment #7 IRB approved 10/13/2022: The study will no longer enroll to Arm B. Cabiralizumab will no longer be given. The hypothesis of this study is that on-treatment tumor associated macrophages (TAMs) and tumor infiltrating lymphocytes (TILs) will improve (reduced TAMs, increased TILs) following neoadjuvant nivolumab with chemotherapy.
Percent Change in Tumor Infiltrating Lymphocytes (TILs)
Baseline and week 5 · percent change
| Arm A and Unrandomized Arm: Neoadjuvant Chemo + Nivolumab | 95.2 ± 121 percent change |
|---|
| Arm B: Neoadjuvant Chemo + Nivolumab + Cabiralizumab | 1.63 ± 82.5 percent change |
|---|
Percent Change in Tumor Associated Macrophages (TAMs)
Baseline and week 5 · percent change
| Arm A and Unrandomized Arm: Neoadjuvant Chemo + Nivolumab | 31.8 ± 32.1 percent change |
|---|
| Arm B: Neoadjuvant Chemo + Nivolumab + Cabiralizumab | -38.7 ± 63.6 percent change |
|---|
Safety of the Regimen as Measured by Incidence of Adverse Events (Safety lead-in Only)
From start of treatment through 100 days after last day of study treatment or surgery whichever occurs first (approximately 16 weeks) · Participants
| Arm A: Neoadjuvant Chemo + Nivolumab | 4 Participants |
|---|
| Arm B: Neoadjuvant Chemo + Nivolumab + Cabiralizumab | 2 Participants |
|---|
| Arm A: Neoadjuvant Chemo + Nivolumab | 2 Participants |
|---|
| Arm B: Neoadjuvant Chemo + Nivolumab + Cabiralizumab | 4 Participants |
|---|
| Arm A: Neoadjuvant Chemo + Nivolumab | 1 Participants |
|---|
| Arm B: Neoadjuvant Chemo + Nivolumab + Cabiralizumab | 0 Participants |
|---|
BENITIONS에서 보기
ClinicalTrials.gov 원문 보기
전체 임상
이 페이지는 ClinicalTrials.gov의 공개 데이터를 정리한 것입니다. 의학적 조언이 아니며 투자 권유나 자문도 아닙니다. 반드시 전문의와 상담하세요.